Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Cisplatin

Antimetabolites

GP (Gemcitabine and Cisplatin combination)

ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1

ABX, cisplatin

Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1

Gemcitabine, Cisplatin

Xichun Hu, MD, PhD

ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

A Phase III, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer

Fudan University

Carboplatin

GP (gemcitabine and cisplatin combination)

GC (gemcitabine and carboplatin combination)

Gemcitabine,cisplatin

Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1

Gemcitabine,carboplatin

Biyun Wang, MD

Xichun Hu, MD,PhD

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Carboplatin (GC) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer.

A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Carboplatin (GC) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)	NCT02546934	Breast Cancer	ABX, cisplatin Gemcitabine, Ci...	18 Years - 70 Years	Fudan University
ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)	NCT02546934	Breast Cancer	ABX, cisplatin Gemcitabine, Ci...	18 Years - 70 Years	Fudan University
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)	NCT02341911	Breast Cancer	Gemcitabine,cis... Gemcitabine,car...	18 Years - 70 Years	Fudan University

Spots Global Cancer Trial Database for fine line chemotherapy